Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
1.820
-0.010 (-0.55%)
At close: May 18, 2026, 4:00 PM EDT
1.820
0.00 (0.00%)
Pre-market: May 19, 2026, 5:04 AM EDT

Tempest Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
16.0913.9713.5511.6612.119.82
Research & Development
27.2712.6128.4817.522.5317.17
Total Operating Expenses
43.3626.5842.0329.1634.6426.99
Operating Income
-43.36-26.58-42.03-29.16-34.64-26.99
Interest Income
0.350.732.822.562.171.25
Other Non-Operating Income (Expense)
0.240.310.18-0.33-1.07-1.32
Total Non-Operating Income (Expense)
0.591.0432.231.1-0.07
Pretax Income
-42.77-25.54-39.03-26.93-33.54-27.05
Net Income
-43.1-26.26-41.84-29.49-35.71-28.3
Net Income to Common
-43.1-26.26-41.84-29.49-35.71-28.3
Shares Outstanding (Basic)
642110
Shares Outstanding (Diluted)
642110
Shares Change (YoY)
133.56%93.34%80.99%33.49%204.70%709.62%
EPS (Basic)
-6.01-6.33-19.50-24.83-40.17-97.11
EPS (Diluted)
-6.01-6.33-19.50-24.83-40.17-97.11
Shares Outstanding
14.344.933.381.70.810.53
Free Cash Flow
-26.38-26.82-33.46-27.53-31.63-26.09
Free Cash Flow Per Share
-4.38-6.46-15.59-23.21-35.61-89.49
EBITDA
-43.1-26.31-41.64-28.78-34-26.61
EBIT
-43.36-26.58-42.03-29.16-34.64-26.99
Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q